Introduction: Despite advances in pharmacotherapy of schizophrenia-spectrum disorders, a
large percentage of persons with schizophrenia remain at least partially nonresponsive to …

The currently available antipsychotics mostly treat the positive symptoms of schizophrenia
and have at least one adverse effect as a potential liability. Encouraging data suggest …

This article reviews the existing evidence for the efficacy and effectiveness of conventional
antipsychotic medications in the treatment of schizophrenia. Among the issues reviewed are …

These guidelines from the British Association for Psychopharmacology address the scope
and targets of pharmacological treatment for schizophrenia. A consensus meeting, involving …

Early-onset schizophrenia (EOS)–onset before age 18–is linked with great disease burden
and disability. Decision-making for EOS pharmacological treatment may be challenging due …

Schizophrenia is a chronic and often severe mental disorder for which antipsychotic drugs
are the cornerstone of treatment. Although the essential mechanism of action of these drugs …

This review covers studies wherein therapeutic effects and adverse events of these drugs in
schizophrenia patients were compared in head-to-head studies and that were published in …

Traditionally, schizophrenia was considered to be a severe psychiatric disorder, with a
chronic course and an unfavorable outcome. Throughout history, there has been incidence …

Background/objective: Schizophrenia is a chronic and disabling psychiatric disorder that
requires lifelong medication. The past 15 years led to the introduction of a number of new …

Schizophrenia remains one of the most severe medical diseases. Current dopamine
modulating first-generation and second-generation antipsychotics target mainly positive …